These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 3011724)
21. Activity of cefoperazone and two beta-lactamase inhibitors, sulbactam and clavulanic acid, against Bacteroides spp. correlated with beta-lactamase production. Crosby MA; Gump DW Antimicrob Agents Chemother; 1982 Sep; 22(3):398-405. PubMed ID: 6291451 [TBL] [Abstract][Full Text] [Related]
22. In vitro activity of beta-lactamase inhibitors against clinical isolates of Acinetobacter species. Suh B; Shapiro T; Jones R; Satishchandran V; Truant AL Diagn Microbiol Infect Dis; 1995 Feb; 21(2):111-4. PubMed ID: 7628190 [TBL] [Abstract][Full Text] [Related]
23. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam. Piddock LJ; Jin YF; Turner HL J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105 [TBL] [Abstract][Full Text] [Related]
24. Beta-lactamase inhibition by acetylmethylene penicillanic acid compared to that of clavulanate and sulbactam. Chin NX; McElrath MJ; Neu HC Chemotherapy; 1988; 34(4):318-25. PubMed ID: 2850139 [TBL] [Abstract][Full Text] [Related]
25. [Sulbactam and clavulanic acid: studies of enzyme kinetics and synergism with ampicillin and mezlocillin]. Cullmann W; Binder S; Stieglitz M Immun Infekt; 1987 May; 15(3):103-9. PubMed ID: 3038733 [TBL] [Abstract][Full Text] [Related]
26. [Activity of sulbactam and clavulanic acid, alone and combined, on Acinetobacter calcoaceticus]. Kitzis MD; Goldstein FW; Labia R; Acar JF Ann Microbiol (Paris); 1983; 134A(2):163-8. PubMed ID: 6307103 [TBL] [Abstract][Full Text] [Related]
27. Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae. Pfaller M; Barry A; Fuchs P; Gerlach E; Hardy D; McLaughlin J Eur J Clin Microbiol Infect Dis; 1993 Mar; 12(3):200-5. PubMed ID: 8389705 [TBL] [Abstract][Full Text] [Related]
28. [The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro]. Blahová J; Hupková M; Krcméry V Cas Lek Cesk; 1995 Sep; 134(17):558-61. PubMed ID: 7553760 [TBL] [Abstract][Full Text] [Related]
29. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors. Qadri SM; Ueno Y; Cunha BA Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972 [TBL] [Abstract][Full Text] [Related]
30. Induction/inhibition of chromosomal beta-lactamases by beta-lactamase inhibitors. Moosdeen F; Keeble J; Williams JD Rev Infect Dis; 1986; 8 Suppl 5():S562-8. PubMed ID: 3026004 [TBL] [Abstract][Full Text] [Related]
31. Influence of beta-lactamase inhibitors on the activity of oxacillin against methicillin-resistant Staphylococcus aureus. Chang SC; Hsieh WC; Luh KT Diagn Microbiol Infect Dis; 1995 Feb; 21(2):81-4. PubMed ID: 7628197 [TBL] [Abstract][Full Text] [Related]
32. Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin. Higashitani F; Hyodo A; Ishida N; Inoue M; Mitsuhashi S J Antimicrob Chemother; 1990 Apr; 25(4):567-74. PubMed ID: 2161820 [TBL] [Abstract][Full Text] [Related]
33. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli. Jacobs MR; Aronoff SC; Johenning S; Shlaes DM; Yamabe S Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017 [TBL] [Abstract][Full Text] [Related]
34. Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli to 12 beta-lactam agents and combinations with beta-lactamase inhibitors. Tajada P; Gomez-Graces JL; Alós JI; Balas D; Cogollos R Antimicrob Agents Chemother; 1996 Aug; 40(8):1924-5. PubMed ID: 8843305 [TBL] [Abstract][Full Text] [Related]
35. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam. Sader HS; Tosin I; Sejas L; Miranda E Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842 [TBL] [Abstract][Full Text] [Related]
36. In vitro activity of YTR 830. Jacobs MR; Aronoff SC; Appelbaum PC; Yamabe S J Chemother; 1989 Jun; 1(3):151-4. PubMed ID: 2552029 [TBL] [Abstract][Full Text] [Related]
37. Antibacterial activity of ticarcillin in the presence of clavulanate potassium. Sutherland R; Beale AS; Boon RJ; Griffin KE; Slocombe B; Stokes DH; White AR Am J Med; 1985 Nov; 79(5B):13-24. PubMed ID: 3878080 [TBL] [Abstract][Full Text] [Related]
38. 6-Acetylmethylenepenicillanic acid (Ro 15-1903), a potent beta-lactamase inhibitor. II. Antibacterial properties. Angehrn P; Arisawa M J Antibiot (Tokyo); 1982 Nov; 35(11):1584-9. PubMed ID: 6298168 [TBL] [Abstract][Full Text] [Related]
39. In vitro evaluation of SF-2103A, a novel carbapenem antibiotic, as a beta-lactamase inhibitor. Niwa T; Yoshida T; Tamura A; Kazuno Y; Inouye S; Ito T; Kojima M J Antibiot (Tokyo); 1986 Jul; 39(7):943-55. PubMed ID: 3019978 [TBL] [Abstract][Full Text] [Related]
40. In vitro activity of cefodizime (HR-221) in combination with beta-lactamase inhibitors. Segatore B; Perilli M; Franceschini N; Setacci D; Oratore A; Amicosante G J Chemother; 1993 Jun; 5(3):147-50. PubMed ID: 8396624 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]